Pathstone Family Office’s Neurogene NGNE Stock Holding History

Pathstone Family Office’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$28K	–	1106
2020 Q4	$28K	Buy	+100	New	+$24.4K	﹤0.01%	624

Other funds holding NGNE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Pathstone Family Office's NGNE Position: Q1 2021 in Review

Pathstone Family Office sold out of Neurogene (NGNE) in Q1 2021, closing a stake of 100 shares — an estimated $28K sold.

Pathstone Family Office first reported a position in NGNE in Q4 2020 and held it in 1 quarter. The position peaked at $28K in Q4 2020. 82 funds tracked by Wall St. Rank hold NGNE as of Q1 2021.

Pathstone Family Office reported no remaining Neurogene position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 100 Neurogene shares in Q1 2021, an estimated $28K.
Pathstone Family Office first reported a position in Neurogene in Q4 2020 and held it in 1 quarter.
Pathstone Family Office's Neurogene position peaked at $28K in Q4 2020.
82 funds tracked by Wall St. Rank held Neurogene as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.